Cargando…
TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway
Osteosarcoma is the most common type of bone cancer, and the second leading cause of cancer-related death in children and young adults. Osteosarcoma stem cells are essential for osteosarcoma initiation, metastasis, chemoresistance and recurrence. In the present study, we report that: 1) higher TSSC3...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689636/ https://www.ncbi.nlm.nih.gov/pubmed/29156746 http://dx.doi.org/10.18632/oncotarget.20429 |
_version_ | 1783279423054675968 |
---|---|
author | Yan, Guang-Ning Tang, Xue-Feng Zhang, Xian-Chao He, Ting Huang, Yu-Sheng Zhang, Xi Meng, Gang Guo, De-Yu Lv, Yang-Fan Guo, Qiao-Nan |
author_facet | Yan, Guang-Ning Tang, Xue-Feng Zhang, Xian-Chao He, Ting Huang, Yu-Sheng Zhang, Xi Meng, Gang Guo, De-Yu Lv, Yang-Fan Guo, Qiao-Nan |
author_sort | Yan, Guang-Ning |
collection | PubMed |
description | Osteosarcoma is the most common type of bone cancer, and the second leading cause of cancer-related death in children and young adults. Osteosarcoma stem cells are essential for osteosarcoma initiation, metastasis, chemoresistance and recurrence. In the present study, we report that: 1) higher TSSC3 expression indicates a better prognosis for osteosarcoma patients, and; 2) overexpression of TSSC3 significantly decreases sphere-forming capacity, tumor initiation, stemness-related surface markers and Nanog expression in osteosarcoma cells. We also discovered that higher Nanog expression correlates to a worse prognosis for osteosarcoma patients, and overexpression of Nanog increases the stem-related phenotype in osteosarcoma cells. Knockdown of Nanog suppresses these phenotypes. Inhibition of Nanog expression and self-renewal of osteosarcoma cells by TSSC3 overexpression appears to be mediated through inactivation of the Src/Akt pathway. In the clinical setting, expression of TSSC3, p-Src and Nanog is associated with recurrence, metastasis and surgical intervention. Lower TSSC3 expression, higher Nanog expression or higher p-Src expression indicate a poor prognosis for osteosarcoma patients. Overall, our study demonstrates that TSSC3 inhibits the stem-like phenotype and Nanog expression by inactivation of the Src/Akt pathway; this emphasizes the importance of Nanog in osteosarcoma stem cells. |
format | Online Article Text |
id | pubmed-5689636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56896362017-11-17 TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway Yan, Guang-Ning Tang, Xue-Feng Zhang, Xian-Chao He, Ting Huang, Yu-Sheng Zhang, Xi Meng, Gang Guo, De-Yu Lv, Yang-Fan Guo, Qiao-Nan Oncotarget Research Paper Osteosarcoma is the most common type of bone cancer, and the second leading cause of cancer-related death in children and young adults. Osteosarcoma stem cells are essential for osteosarcoma initiation, metastasis, chemoresistance and recurrence. In the present study, we report that: 1) higher TSSC3 expression indicates a better prognosis for osteosarcoma patients, and; 2) overexpression of TSSC3 significantly decreases sphere-forming capacity, tumor initiation, stemness-related surface markers and Nanog expression in osteosarcoma cells. We also discovered that higher Nanog expression correlates to a worse prognosis for osteosarcoma patients, and overexpression of Nanog increases the stem-related phenotype in osteosarcoma cells. Knockdown of Nanog suppresses these phenotypes. Inhibition of Nanog expression and self-renewal of osteosarcoma cells by TSSC3 overexpression appears to be mediated through inactivation of the Src/Akt pathway. In the clinical setting, expression of TSSC3, p-Src and Nanog is associated with recurrence, metastasis and surgical intervention. Lower TSSC3 expression, higher Nanog expression or higher p-Src expression indicate a poor prognosis for osteosarcoma patients. Overall, our study demonstrates that TSSC3 inhibits the stem-like phenotype and Nanog expression by inactivation of the Src/Akt pathway; this emphasizes the importance of Nanog in osteosarcoma stem cells. Impact Journals LLC 2017-08-24 /pmc/articles/PMC5689636/ /pubmed/29156746 http://dx.doi.org/10.18632/oncotarget.20429 Text en Copyright: © 2017 Yan et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Yan, Guang-Ning Tang, Xue-Feng Zhang, Xian-Chao He, Ting Huang, Yu-Sheng Zhang, Xi Meng, Gang Guo, De-Yu Lv, Yang-Fan Guo, Qiao-Nan TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway |
title | TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway |
title_full | TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway |
title_fullStr | TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway |
title_full_unstemmed | TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway |
title_short | TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway |
title_sort | tssc3 represses self-renewal of osteosarcoma stem cells and nanog expression by inhibiting the src/akt pathway |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689636/ https://www.ncbi.nlm.nih.gov/pubmed/29156746 http://dx.doi.org/10.18632/oncotarget.20429 |
work_keys_str_mv | AT yanguangning tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT tangxuefeng tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT zhangxianchao tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT heting tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT huangyusheng tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT zhangxi tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT menggang tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT guodeyu tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT lvyangfan tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway AT guoqiaonan tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway |